Company news

Vistagen Therapeutics, Inc. news in 2023

Vistagen Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain

December 26, 2023

Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results

November 8, 2023

Vistagen Announces Pricing of $100 Million Underwritten Offering

October 1, 2023

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder

September 11, 2023

Vistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagen’s Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan

September 4, 2023

Vistagen Appoints Cindy Anderson as Chief Financial Officer

August 21, 2023

Vistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder

August 6, 2023

Vistagen Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Spray’s Potential Antidepressant Activity via Peripheral Nasal Neurons without Entry into the Brain

July 16, 2023

Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease

July 12, 2023

Vistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results

June 27, 2023

Vistagen to Announce Fiscal Year 2023 Financial Results and Provide Corporate Update Conference Call on June 28, 2023

June 26, 2023

Vistagen Regains Full Compliance with Nasdaq Listing Requirements

June 22, 2023

Vistagen Announces Results of Successful U.S. Phase 1 Study of Itruvone (PH10), Enabling U.S. Phase 2B Development for Treatment of Major Depressive Disorder

June 20, 2023

Vistagen Announces European Patent Office Intention to Grant New PH80 Nasal Spray Patent for the Treatment of Migraine

June 12, 2023

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 in Women Diagnosed with Menopausal Hot Flashes

June 6, 2023

Vistagen Announces Stockholder-Approved Reverse Stock Split

June 5, 2023

Vistagen Receives New European Patent for AV-101

April 5, 2023

Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 Open-Label Study in Adults with Social Anxiety Disorder

March 21, 2023

Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder

March 7, 2023

Vistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migraine

February 28, 2023

Vistagen Provides Corporate Update and Reports Fiscal 2023 Third Quarter Financial Results

February 6, 2023

Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023

February 5, 2023

Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition

February 1, 2023

Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder

January 23, 2023

Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In First Quarter Of 2023

January 18, 2023

Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety

January 9, 2023

Calls in 2023

Decks in 2023